Upload
nikko-nugraha
View
244
Download
0
Embed Size (px)
Citation preview
8/9/2019 Guidelines scad
1/52
European guidelines onthe management of
stable coronary arterydisease
Dr Nikko Nugraha
ESC2013
8/9/2019 Guidelines scad
2/52
These guidelines should be applied topatients suspected coronary artery
disease (SCAD)
8/9/2019 Guidelines scad
3/52
Stable coronary artery disease
SCAD characterized by episodes of reversiblemyocardial demand/supply mismatch, related toischaemia or hypoxia, inducible by exercise,emotion or other stress, or spontaneously
he prevalence ! to "# in $omen aged %!&'%
years to ()&(*# in $omen aged '!&+% and % to"# in men aged %!&'% years to (*&(%# inmen aged '!&+%
mortality rates (* to *%#, incidence of cardiac
death bet$een )' and (%# and of non-fatalmyocardial infarction .01 2 )'# and *"#
8/9/2019 Guidelines scad
4/52
Symptoms and Signs
he characteristics of discomfort caused bymyocardial ischaemia is usually located in thechest, near the sternum, but may be feltany$here from the epigastrium to the lo$er 3a$
or teeth, bet$een the shoulder blades or in eitherarm to the $rist and 4ngers
described as pressure, tightness or heaviness5sometimes strangling, constricting or burning
he diagnosis and assessment of SCAD involvesclinical evaluation, including biochemical riskfactors and speci4c cardiac investigations
8/9/2019 Guidelines scad
5/52
8/9/2019 Guidelines scad
6/52
8/9/2019 Guidelines scad
7/52
8/9/2019 Guidelines scad
8/52
Non-invasive cardiacinvestigations
8/9/2019 Guidelines scad
9/52
8/9/2019 Guidelines scad
10/52
Three maor steps used fordecision-ma!ing
8/9/2019 Guidelines scad
11/52
"rinciples of diagnostictesting
8/9/2019 Guidelines scad
12/52
Stress testing for diagnosingischaemia
6lectrocardiogram exercise testing he maindiagnostic 6C7 abnormality during 6C7 exercisetesting consists of a horizontal or do$n-sloping S-
segment depression )( m8, persisting for at least
))'&))+ s after the 9-point, in one or more 6C7leads
he main value of exercise 6C7 testing is in patients$ith normal resting 6C7s
0nconclusive exercise 6C7s are common and in these
patients an alternative non-invasive imaging test often$ith pharmacological stress should be selected 0npatients at lo$ intermediate pre-test probability,
coronary CA is another option
8/9/2019 Guidelines scad
13/52
8/9/2019 Guidelines scad
14/52
8/9/2019 Guidelines scad
15/52
8/9/2019 Guidelines scad
16/52
8/9/2019 Guidelines scad
17/52
Stress imaging
8/9/2019 Guidelines scad
18/52
8/9/2019 Guidelines scad
19/52
yocardial perfusion scintigraphy .S:6C/:612echnetium ;;m .;;mc1 radiopharmaceuticalsare the most commonly used tracers, employed$ith single photon emission computed
tomography .S:6C1 in association $ith asymptom-limited exercise test on either abicycle ergometer or a treadmill
Stress cardiac magnetic resonance2 Cues @ccasional side- eects include oral,intestinal and perianal ulceration
rimetazidine is an anti-ischaemic metabolic modulatorrimetazidine added to beta-blockade improved eort-in- ducedmyocardial ischaemia
8/9/2019 Guidelines scad
39/52
8/9/2019 Guidelines scad
40/52
8/9/2019 Guidelines scad
41/52
8/9/2019 Guidelines scad
42/52
8/9/2019 Guidelines scad
43/52
Event prevention
Antiplatelet in prevention of ischaemic events andaspirin is the drug of choice he use of antiplateletagents is associated $ith a higher bleeding risk
Clopidogrel is a second-line treatment for aspirin-intolerant C8D patients
:rasugrel and ticagrelor are ne$ :*I(* antagonists thatachieve greater platelet inhibition, compared $ithclopidogrel
Dual antiplatelet therapy combining aspirin and athienopyridine is the standard of care for patients $ith
ACS :latelet function testing in SCAD patients undergoing :C0
is not recommended as a routine
8/9/2019 Guidelines scad
44/52
SCAD patients should be treated $ith statin $ith a target of D-C J
(+ mmol/l and/or =!)# reduction AC6 inhibitors reduce total mortality, 0 stroke and heart failure in
patients $ith co-existing hypertension, 86F %)#, diabetes orCKD A
8/9/2019 Guidelines scad
45/52
Adding ivabradine 7.5 mg twice daily to atenolol therapy gave better control of heart rate and
anginal symptoms.
In 1507 patients with prior angina enrolled in the MorbidityMortality !val"ation of the If Inhibitor
Ivabradine in #atients $ith %oronary Artery &isease and 'eft (entric"lar &ysf"nction
)*!A+,I-+' trial/ ivabradine reduced the composite primary end point of CV death,
hospitalization with MI and !, and reduced hospitalization for MI. ,he effect was
predominant in patients with a heart rate 70 bpm.
Ivabradine is thus an effective anti"anginal agent, alone or in combination with #"bloc$ers .
Ne& ESC guidelines and$vabradine
Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coona! ate! disease" #he #as$ %oce on the management of stable coona! ate!
disease of the Euo&ean Societ! of Cadiolog!. Eur Heart J. 2013'3()3*+"2(-3003.
Ne& ESC guidelines and
8/9/2019 Guidelines scad
46/52
Ne& ESC guidelines andTrimeta+idine
Trimetazidine is an anti-ischemic metabolic modulator, with similar anti-
anginal efficacy to propranolol in doses of 20 mg thrice daily.
Trimetazidine (35 mg twice daily) added to -blockade (atenolol)improved effort-induced myocardial ischemia, as re!iewed by the E"# in
June 20$2.
%n diabetic persons Trimetazidine improved !b"#c and glycemia, while
increasing forearm glucose u&ta'e.
Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coona! ate! disease" #he #as$ %oce on the management of stable coona! ate!
disease of the Euo&ean Societ! of Cadiolog!. Eur Heart J. 2013'3()3*+"2(-3003.
8/9/2019 Guidelines scad
47/52
,evasculari+ation
?are metal stents .?S1 are associated $ith a*)&G)# rate of angiographic stenosis $ithin '&;months after implantation
Drug-eluting stents .D6S1 reduce the incidenceof restenosis and ischaemia-driven repeatrevascularization
Coronary artery bypass surgery
Lhen technically feasible, $ith an acceptablelevel of risk and a good life expectancy,revascularization is indicated in chronicangina refractory to @
8/9/2019 Guidelines scad
48/52
8/9/2019 Guidelines scad
49/52
,evasculari+ation "rocedure
8/9/2019 Guidelines scad
50/52
8/9/2019 Guidelines scad
51/52
Women
Lomen more fre>uently have CAD $ith stable angina and noobstructive coronary disease
Lomen are more likely to have complications from revascularization
Diabetic patients Need dierent risk factor management
lder patients Eigh-risk group $ith higher mortality and higher rates of myocardial
infarction
Msually undertreated, receiving less drugs
Dicult diagnosis due to atypical symptoms
Eigher risk of complications during and after coronary revascularization
Comorbidities!intolerance Depending on comorbidities/tolerance, it is indicated to use second-line
therapies as 4rst-line treatment in selected patients
Speci%c patient pro%les
8/9/2019 Guidelines scad
52/52
Conclusion
ESC Guidelines highlighted two aims fo the &hamacological management
of stable CA &atients" obtain elief of s!m&toms and &e/ent cadio/asculae/ents.
CA &atients should all ecei/e aspirin and a statin, plus an ACE inhibitor
in case of comobidities.
-blockers or CCBs should be &escibed as fist-line teatment to educe
angina.
Ivabradine and Trimetazidine )as ell as long-acting nitates, nicoandil and
anolaine+ ae ecommended second-line, in combination ith fist-lineteatment, in &atients emaining s!m&tomatic.
h!sicians should conside optimal medical treatment befoe
e/asculaiation &ocedues.